US Bancorp’s Gyre Therapeutics GYRE Stock Holding History

US Bancorp’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$683	Buy	+98	New	+$761	﹤0.01%	3975
2025 Q2	–	Sell	-17	Closed	-$131	–	4228
2025 Q1	$131	Buy	+17	New	+$186	﹤0.01%	4128

Other funds holding GYRE

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

US Bancorp's GYRE Position: Q1 2026 in Review

US Bancorp opened a new position in Gyre Therapeutics (GYRE) in Q1 2026: 98 shares worth $683. The stake represents ﹤0.01% of the portfolio and ranks #3975 among its holdings. This is a return to the name: US Bancorp previously reported a position in GYRE as recently as Q1 2025.

US Bancorp first reported a position in GYRE in Q1 2025 and has held it in 2 quarters since. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.

US Bancorp held 98 shares of Gyre Therapeutics worth $683 as of Q1 2026.
Gyre Therapeutics was a new US Bancorp position in Q1 2026.
Gyre Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3975 holding.
US Bancorp first reported a position in Gyre Therapeutics in Q1 2025 and has held it in 2 quarters since.
56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.